Bank Of America Corp Relmada Therapeutics, Inc. Transaction History

Bank Of America Corp

$1.19 Trillion
Q3 2024

A detailed history of Bank Of America Corp transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 206,658 shares of RLMD stock, worth $570,376. This represents 0.0% of its overall portfolio holdings.

Number of Shares

206,658

Previous 207,969 0.63%

Holding current value

$570,376

Previous $623,000 7.38%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$2.3 - $4.36 $3,015 - $5,715	-1,311 Reduced 0.63%	206,658 $669,000
Q2 2024 Aug 14, 2024	SELL	$2.93 - $4.94 $7,638 - $12,878	-2,607 Reduced 1.24%	207,969 $623,000
Q1 2024 May 15, 2024	SELL	$3.1 - $6.8 $170 - $374	-55 Reduced 0.03%	210,576 $979,000
Q4 2023 Feb 14, 2024	SELL	$2.45 - $4.22 $64,361 - $110,859	-26,270 Reduced 11.09%	210,631 $872,000
Q2 2023 Aug 14, 2023	BUY	$2.22 - $3.54 $443,038 - $706,467	199,567 Added 534.54%	236,901 $582,000
Q1 2023 May 12, 2023	BUY	$2.24 - $4.76 $46,533 - $98,884	20,774 Added 125.45%	37,334 $84,000
Q4 2022 Feb 10, 2023	BUY	$2.17 - $35.84 $5,848 - $96,588	2,695 Added 19.44%	16,560 $57,000
Q3 2022 Nov 14, 2022	BUY	$18.3 - $37.02 $92,927 - $187,987	5,078 Added 57.79%	13,865 $513,000
Q2 2022 Aug 12, 2022	BUY	$16.5 - $30.34 $33,841 - $62,227	2,051 Added 30.45%	8,787 $166,000
Q1 2022 May 16, 2022	SELL	$16.72 - $26.99 $61,362 - $99,053	-3,670 Reduced 35.27%	6,736 $182,000
Q4 2021 Feb 08, 2022	SELL	$16.93 - $26.82 $31,743 - $50,287	-1,875 Reduced 15.27%	10,406 $235,000
Q3 2021 Nov 15, 2021	BUY	$21.86 - $34.77 $132,996 - $211,540	6,084 Added 98.18%	12,281 $322,000
Q2 2021 Sep 13, 2021	BUY	$29.55 - $39.15 $183,121 - $242,612	6,197 New	6,197 $199,000

Others Institutions Holding RLMD

# of Institutions

Shares Held

12.3M

Call Options Held

229K

Put Options Held

138K

View Full List

About RELMADA THERAPEUTICS, INC.

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $79M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

More about RLMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Relmada Therapeutics, Inc. Transaction History